UPC_CFI_1/2023

ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

RevocationMain Revocation ActionMunich CDRevocationCase Closed

Overview Decisions Reasoning Citations Documents Timeline

Parties

Claimants

Sanofi-Aventis Deutschland GmbH(Sanofi Group)

Reps: Daniel Wise

Respondents

Amgen Inc.(Amgen Group)

Reps: Koen Bijvank

Judges

Ulrike Voß
Andras Kupecz
Casper Struve

Patents

EP3666797
EP 3 666 797

CPC codes: C07K2317/14, C07K2317/34, A61K39/395, A61K2039/505, A61K31/366, A61P3/06, A61K31/66, A61K31/22, A61P9/00, A61P7/00, A61P25/28, A61K2300/00…

Technology area: Biotech · Antibody

Sector: Biotechnology

Outcome

RevokedRevoked in full

Filed: Jun 2, 2023

First decided: Jun 29, 2023

Last decision: Feb 24, 2024

Language: English

The Munich Central Division (UPC's first-ever revocation case) revoked European patent EP 3 666 797 B1 (relating to an anti-PCSK9 antibody composition for treating hypercholesterolaemia, owned by Amgen) in its entirety for the territories of 17 UPC Contracting Member States. The patent was found to lack inventive step. All 17 auxiliary requests were also found to lack inventive step. Amgen (defendant/patent proprietor) was ordered to bear Sanofi's legal costs of EUR 1,375,000.

Open on UPC Registry

Claims

At issueall

Revokedall

Notes: EP 3 666 797 B1 revoked entirely (UPC's first revocation case); Main Request and all 17 Auxiliary Requests lacked inventive step.